Short Interest in MetaVia Inc. (NASDAQ:MTVA) Declines By 69.4%

MetaVia Inc. (NASDAQ:MTVA) saw a significant drop in short interest during the month of December. As of December 15th, there was short interest totaling 60,602 shares, a drop of 69.4% from the November 30th total of 198,092 shares. Based on an average trading volume of 425,605 shares, the days-to-cover ratio is presently 0.1 days. Currently, 2.8% of the company’s shares are short sold. Currently, 2.8% of the company’s shares are short sold. Based on an average trading volume of 425,605 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Upgrades and Downgrades

MTVA has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MetaVia in a research report on Monday. HC Wainwright started coverage on shares of MetaVia in a research note on Thursday, September 4th. They issued a “buy” rating and a $132.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $82.50.

MetaVia Price Performance

Shares of MetaVia stock opened at $9.76 on Thursday. The stock’s 50-day moving average is $9.20 and its 200 day moving average is $8.67. MetaVia has a one year low of $6.05 and a one year high of $30.25. The firm has a market cap of $21.47 million, a price-to-earnings ratio of -1.17 and a beta of 0.29.

MetaVia (NASDAQ:MTVA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.86) by $1.32. On average, sell-side analysts expect that MetaVia will post -3.9 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in MetaVia stock. SG Americas Securities LLC boosted its stake in MetaVia Inc. (NASDAQ:MTVA) by 44.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 60,386 shares of the company’s stock after purchasing an additional 18,506 shares during the quarter. SG Americas Securities LLC owned about 0.25% of MetaVia worth $57,000 as of its most recent SEC filing. Institutional investors own 1.37% of the company’s stock.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.